Publication details
Metabolický syndrom u pacientů po prodělané protinádorové terapii
| Title in English | Anti-cancer therapy-induced metabolic syndrome |
|---|---|
| Authors | |
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | Vnitřní lékařství |
| MU Faculty or unit | |
| Citation | |
| web | https://www.casopisvnitrnilekarstvi.cz/artkey/vnl-202106-0004_anti-cancer-therapy-induced-metabolic-syndrome.php |
| Doi | http://dx.doi.org/10.36290/vnl.2021.089 |
| Keywords | oncology; metabolic syndrome; anti-cancer therapy |
| Description | The increasing number of long-term survivors that underwent the anti-cancer therapy faces the late treatment-related adverse effects and the increased risk of developing metabolic syndrome. This article defines the pathophysiology that underlies development of anti-cancer therapy-related metabolic syndrome and outlines the possibility of optimisation of comprehensive care focusing on prevention. Considering the preventability of metabolic syndrome, effective screening and follow-up appropriate for patients at increased risk of related adverse events should be established. Subsequently, early initiation of therapy targeting the hallmarks of metabolic syndrome may ease its manifestation in long-term perspective. |